15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering MEDIFAST INC, 0 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a hold consensus. Targets are tightly clustered, $12.00 to $12.00, so the covering firms are broadly aligned. The average target of $12.00 sits 1% below the current $12.17. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.12 next quarter toward $-0.28 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Hold
Strong Buy00%
Buy00%
Hold1100%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to MEDIFAST INC.
As of Sep, 0 of 1 firms rate MED a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
MED EPS & revenue forecast
EPS · NEXT QUARTER
$-0.12
Range $-0.12 – $-0.12 · 1 analysts · -93% YoY
Next period, 1 analysts expect MEDIFAST INC to earn $-0.12 a share (range $-0.12 – $-0.12), versus $-1.65 a year earlier. Full-year consensus is $-1.15, growing to $-0.28 the year after.
REVENUE · NEXT QUARTER
$64.1M
Range $64.1M – $64.1M · 1 analysts · -15% YoY
Revenue is expected to reach $64.1M (range $64.1M – $64.1M), -14.6% year-over-year. Full-year consensus is $287.7M, rising to $273.7M next year.
Top analysts covering MEDIFAST INC
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MED.
#1
Linda Bolton Weiser
DA Davidson · Rank #393
Hold
$16.50+35.6% to target
Overall win rate
29%
+ Follow
#2
Jim Salera
Stephens & Co. · Rank #447
Hold
$12.00-1.4% to target
Overall win rate
19%
+ Follow
MED stock forecast FAQ
What is MED's average 12-month price target?+
The 1 analysts with a live target average $12.00 for MEDIFAST INC over the next 12 months, ranging from a $12.00 high to a $12.00 low.
Is MED stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 1 analyst ratings, 0 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover MED?+
1 analysts have an active rating on MEDIFAST INC, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering MED?+
Among analysts who currently cover MED, Linda Bolton Weiser of DA Davidson has the strongest overall Quantellect track record (Rank #393). Their current call is Hold with a $16.50 target.
What is MEDIFAST INC's projected EPS for next quarter?+
The consensus estimate is $-0.12 per share (range $-0.12 – $-0.12) across 1 analysts. Full-year EPS is projected at $-1.15, rising to $-0.28 the following year.
How much revenue is MEDIFAST INC expected to report next quarter?+
Consensus revenue is $64.1M (range $64.1M – $64.1M). Full-year revenue is projected at $287.7M, growing to $273.7M next year.
Have analysts been upgrading or downgrading MED lately?+
As of Sep, 0 of 1 firms rate MED a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MED calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
